Contact

Our portfolio

Parkinnova Therapeutics

Parkinnova Therapeutics, focuses on developing novel treatments for midbrain dopamine disorders like Parkinson’s disease. The company targets the PDE11a pathway to upregulate dopamine production. Parkinnova aims to bring innovative therapies to clinical trials, addressing significant unmet needs in neurodegenerative diseases. The company is committed to advancing neuroscience through cutting-edge research.

  • Institute: University of Amsterdam
Industry: Neuroscience, Therapeutics
  • Founding year: 2024
Visit website

Want to get in contact about Parkinnova Therapeutics?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Browse all investment managers

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

Regenesance
Engineering antibodies to treat neurodegenerative and immune diseases.
Amplio Pharma
Amplifying treatment of chronic autoimmune diseases.
Scyfer
Developing advanced machine learning and deep learning technologies, Scyfer specializes in applying these solutions across various industries, including industry, media, and healthcare.
Hipper Therapeutics
Boosting recovery and confidence in elderly hip fracture patients with data-driven rehabilitation technology.
Regenesance
Engineering antibodies to treat neurodegenerative and immune diseases.
Amplio Pharma
Amplifying treatment of chronic autoimmune diseases.
Scyfer
Developing advanced machine learning and deep learning technologies, Scyfer specializes in applying these solutions across various industries, including industry, media, and healthcare.
Hipper Therapeutics
Boosting recovery and confidence in elderly hip fracture patients with data-driven rehabilitation technology.
Explore full AAV portfolio
Contact